A Multicenter Random Single Blind Parallelism Drugs Contrast Eeperiment of Treatment of Pristine HAPE with Diffrent Projects

Precaution, prophase diagnose and standard treatment study of rapid get onto plateau personnel acute altitude disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002379

Enrollment

Unknown

Registered

2012-07-25

Start date

2011-06-07

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute altitude disease

Interventions

A group:aminophylline

B group:dexamethasone

C group:nifedipine

Eligibility

Sex/Gender

All

Age

16 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. 18 to 60 years of age; 2. Patient of achieved the diagnostic criteria of early HAPE Agreement; 3. Patients signed the informed consent.

Exclusion criteria

Exclusion criteria: Severe heart, brain, liver, kidney and other serious diseases; Diagnostic criteria for 1995 China High Altitude Medicine HAPE; Patient of mental, nervous system diseases; Advanced tumors; Pregnancy, breast-feeding women; Poor compliance patient that is difficult to complete the treatment; Severe immune function defect; Drug and(or) narcotics abuse.

Design outcomes

Primary

Measure	Time frame
recovery rate;progressed HAPE incidence rate;	—

Secondary

Measure	Time frame
average recovery time;average time to be in hospital;Adverse Event incidence rate;	—

Countries

China

Contacts

Public ContactJancheng Xu

xu822036@sohu.com+86 13708320902

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026